Coexistence of Heavy Drinking and Obesity Raises Liver Disease Risk, Finds JAMA Study
USA: Researchers have found in a nationally representative study that nearly 1 in 10 U.S. adults in 2023 had both heavy alcohol use and obesity, significantly increasing the risk of alcohol-related liver disease. The findings highlight the need for targeted public health and clinical interventions, particularly among younger and middle-aged adults, and those with limited or no insurance, to prevent rising liver disease burden.
The study, published as a Research Letter in JAMA Internal Medicine, was led by Bryant Shuey from the Center for Research on Healthcare, Division of General Internal Medicine, University of Pittsburgh, and colleagues. It sheds light on the growing overlap between two modifiable risk factors—excess alcohol consumption and obesity—both of which independently contribute to liver disease but may have an even greater combined impact when present together.
Over recent decades, both heavy drinking and obesity have become increasingly common in the United States. However, data on how frequently these conditions coexist, particularly in the post–COVID-19 period, have been limited. The researchers addressed this gap by analyzing nationally representative survey data to estimate the prevalence of concurrent heavy alcohol use, obesity, and alcohol use disorder (AUD) among adults.
Key Findings:
- The overlap between heavy alcohol use and obesity is considerable and may start earlier in life than previously recognized.
- Younger and middle-aged adults exhibit the highest rates of co-occurrence.
- Multiple risk factors for liver disease tend to accumulate long before symptoms become evident.
- This early overlap raises concerns about a potential rise in advanced liver disease if timely preventive measures are not implemented.
- Individuals with both obesity and risky alcohol use may remain asymptomatic for years.
- Liver disease in such individuals often goes undiagnosed until it progresses to advanced stages like cirrhosis.
- When symptoms develop, they may include jaundice, abdominal swelling, and gastrointestinal bleeding, often requiring urgent care.
- Disease progression may result from metabolic dysfunction, alcohol use, or both acting together.
- If left untreated, the condition can progress to liver failure.
The study highlights the need for integrated screening and management of alcohol use and metabolic health to enable early identification of at-risk individuals. Combined, evidence-based strategies—such as behavioral counseling, medications for alcohol use disorder, and therapies targeting metabolic risk—should be implemented together. Emerging options like GLP-1 receptor agonists may provide dual benefits, though further evidence is required.
Key challenges include stigma, limited access to care, and low treatment uptake for alcohol use disorder, along with socioeconomic barriers such as poor access to healthy food and safe spaces for physical activity. The findings stress the importance of prevention-focused approaches and improved healthcare access, particularly for underserved groups.
Overall, the results highlight a crucial opportunity for early intervention, suggesting that tackling heavy alcohol use and obesity together could help reduce the long-term burden of liver disease.
Reference:
Shuey B, Anderson TS, Wharam JF, et al. Heavy Drinking, Alcohol Use Disorder, and Obesity. JAMA Intern Med. Published online April 20, 2026. doi:10.1001/jamainternmed.2026.0428
Next Story